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PreviewsDepression causes morbidity and is a
burden on society (Lawlor and Hopker,
2001). The study by Agudela et al. demon-
strates that skeletal muscle PGC-1a1
overexpression can counteract depres-
sion and acts as an exercise-mimetic that
modulates paracrine factors. Understand-
ing the mechanisms underlying muscle-
to-brain communication may open up
avenues to new therapeutic approaches.
Indeed, it will be important to identify the
key proteins and metabolites that are
dynamically secreted by muscle during
exercise to meet the brain’s physiological
demands. In the future, these may lead to
treatments for a variety of brain disorders,
including psychiatric and cognitive con-
ditions as well as neurodegenerative
diseases.562 Cell Metabolism 20, October 7, 2014 ª20ACKNOWLEDGMENTS
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Periostin is a crucial extracellular remodeling factor in the inflammatory and tumormicroenvironments, but its
function in nonalcoholic fatty liver disease remains unclear. Lu et al. (2014) now demonstrate that periostin is
a critical player in the regulation of hepatic triglyceride homeostasis and the development of obesity-induced
hepatosteatosis.Nonalcoholic fatty liver disease (NAFLD),
one of the most prevalent causes of
chronic liver disease in the Western
world, refers to a clinical metabolic syn-
drome with excessive fat deposition in
the liver not due to alcohol abuse. NAFLD
ranges from simple steatosis to nonalco-
holic steatohepatitis (NASH); the latter in-
cludes and leads to progressive fibrosis
and hepatocellular carcinoma (HCC).
Aberrant triglyceride (TG) accumulation
in hepatocytes is recognized as the hall-
mark of NAFLD. This dysregulated TG
accumulation is closely related to obesity
and metabolic syndrome (Cohen et al.,
2011; Michelotti et al., 2013). In humans,
obesity is strongly associated with hepa-tosteatosis and NASH pathogenesis
(Umemura et al., 2014); however, the
development and progression of hepa-
tosteatosis and steatohepatitis as well
as the mechanisms underlying obesity-
induced fatty liver remain poorly under-
stood. A recent intriguing article in the
Journal of Clinical Investigation demon-
strates that periostin (encoded by Postn)
mediates obesity-induced hepatosteato-
sis (Lu et al., 2014).
To identify genes involved in aberrant
hepatic lipid homeostasis in obesity, Lu
et al. (2014) performed a clustering anal-
ysis of Affymetrix arrays and found that
periostin expression is markedly elevated
in the liver of high-fat-diet-fed mice. Thisphenotype was also observed in ob/ob
and db/db obese mice, as well as in
NAFLD patients, indicating that periostin
overproduction in the liver is a conserved
phenotype in both obese rodents and
humans. Interestingly, hepatic periostin
expression was induced by high glucose
via the transcription factor ChREBP, and
overexpression of periostin in the liver of
C57BL/6 mice resulted in hepatic TG
accumulation and increased liver weight.
Similar results were obtained by treating
HepG2 cells and mouse primary hepato-
cytes (MPHs) with recombinant periostin
protein. These data suggest that perios-
tin promotes TG accumulation in the
liver.
Figure 1. Roles of Periostin in Obesity-Induced Hepatosteatosis and Liver Diseases
(A) Glucose promotes hepatic periostin expression via the transcription factor carbohydrate-responsive
element-binding protein (ChREBP) in obesemice and humans. Periostin binds to a6b4 integrins to activate
the JNK signaling pathway, which at least partly depends on Rac1. Phosphorylated c-Jun prevents RORa
from binding to the Ppara promoter, which results in PPARa downregulation and TG upregulation, finally
leading to hepatosteatosis.
(B) Overexpression of periostin promotes hepatosteatosis; however, whether periostin plays a critical role
in the development of NASH, cirrhosis, and/or HCC still needs to be elucidated.
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PreviewsLu et al. (2014) further found that peri-
ostin promotes liver TG accumulation
via downregulation of PPARa. To deter-
mine which integrins periostin binds to
downregulate PPARa expression, the
authors treated MPHs with integrin anti-
bodies and revealed that periostin binds
to a6b4 integrins, but not avb3 or
avb5 integrins. Periostin has been shown
to promote tumor metastatic growth
through the PI3K/AKT and Wnt/b-catenin
signaling pathways (Bao et al., 2004; Ma-
lanchi et al., 2012; Wang and Ouyang,
2012). However, Lu et al. (2014) demon-
strated that overexpression of periostin
had no impact on the PI3K/AKT pathway,
whereas the JNK pathway was activated.
The JNK kinase inhibitor SP600125 abol-
ished the impact of periostin on liver
weight and TG content in C57BL/6
mice. Moreover, periostin treatment of
MPHs isolated from wild-type mice re-
sulted in a significant increase in cellular
TG content, but not that of MPHs from
Jnk1-knockout mice, confirming that
periostin promotes TG accumulation by
activating the JNK signaling pathway.
The authors further determined that hy-
peractivation of the JNK pathway by
periostin and/or a6b4 integrins is depen-dent on Rac1, an upstream regulator of
JNK signaling.
After determining that periostin down-
regulates PPARa through a6b4 integrin-
mediated JNK activation, Lu et al. (2014)
demonstrated that periostin suppresses
PPARa expression via c-Jun-mediated in-
hibition of RORa transcriptional activity.
Furthermore, Postn shRNA treatment in
the liver of db/db mice attenuated JNK
signaling pathway activation, reduced
hepatic TG accumulation, and improved
hepatosteatosis. Similar results were ob-
tained by comparing Postn heterozygous
mice with wild-type mice. In addition,
treating db/db mice with a neutralizing
antibody against periostin reduced hepat-
ic TG content and improved hepatostea-
tosis. Therefore, these results indicate
that glucose induces periostin expression
via ChREBP, and periostin then binds
to a6b4 integrins to activate the JNK
signaling pathway via Rac1. Phosphory-
lated c-Jun interacts with RORa and
prevents RORa from activating Ppara
gene transcription, which finally results
in TG accumulation and hepatosteatosis
(Figure 1).
Taken together, the work by Lu et al.
(2014) indicates that periostin is likely toCell Metabolism 2be a critical contributing factor in the
development of hepatosteatosis. How-
ever, the findings of Lu et al. (2014) also
raise several interesting points for future
investigation. Apart from glucose and
palmitate, periostin also can be induced
by TGF-b, hypoxia, and Th2 cytokines
(Conway et al., 2014; Liu et al., 2014; Ma-
suoka et al., 2012). Are there other factors
or stresses that can directly or indirectly
induce periostin secretion in the obesity
setting? In addition to hepatocytes, can
stromal cells such as activated hepatic
stellate cells secrete periostin in the
obesity setting? Chronic inflammation is
a critical contributing factor during NASH
pathogenesis. Periostin actively contrib-
utes to various inflammatory diseases
and fibrosis in many tissues; however,
whether periostin is involved in the
progression from liver steatosis to steato-
hepatitis remains unclear. Moreover,
NASH is a more serious form of fatty
liver disease, and some individuals with
steatohepatitis have a higher probability
than those with benign simple steatosis
of developing advanced liver fibrosis,
cirrhosis, and HCC. Periostin has been
shown to be a marker of poor HCC prog-
nosis. Whether and how periostin con-
tributes to liver inflammation-, fibrosis-,
steatohepatitis-, and cirrhosis-associated
HCC still needs to be elucidated. In addi-
tion to interacting with a6b4 integrin re-
ceptors to initiate intracellular signaling
cascades to modulate obesity-induced
hepatosteatosis, periostin may modulate
the development and progression of
various liver diseases by directly or indi-
rectly binding to extracellular macromole-
cules to remodel the biophysical and
biochemical properties of the local liver
tissue microenvironment. In addition,
many other matricellular proteins such
as CCNs, SPARC, tenascins, and osteo-
pontin have been shown to contribute to
the development of liver steatosis, steato-
hepatitis, fibrosis, and/or HCC, so
whether periostin also plays a critical
role in liver fibrosis, cirrhosis, and HCC
similarly to these other matricellular pro-
teins deserves a systemic evaluation. A
wider understanding of the functions and
mechanisms of periostin in liver steatosis,
steatohepatitis, fibrosis, cirrhosis, and
HCCwill provide a promising extracellular
diagnosis biomarker and an excellent
therapeutic target for a wide range of liver
diseases (Figure 1).0, October 7, 2014 ª2014 Elsevier Inc. 563
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